Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma

Takumi Kawaguchi(Kurume University), Takuji Torimura(Omuta hospital)

Journal of Clinical Medicine

March 28, 2020

10.3390/jcm9040936

Cited by 27

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

|Gut|2019|720

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

|American Journal Of Pathology|2004|536

Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)

|Hepatology Research|2023|267

Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)

|PLoS ONE|2020|84

Acute presentation of autoimmune hepatitis: a multicentre study with detailed histological evaluation in a large cohort of patients

|Journal of Clinical Pathology|2017|81